Contact Hypersensitivity Responses Following Ribavirin Treatment In Vivo Are Influenced by Type 1 Cytokine Polarization, Regulation of IL-10 Expression, and Costimulatory Signaling
We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we examined whether type 1 cytokine polarization by ribavirin in vivo could promote contact hypersensitivity (CHS) responses to dinitrofluorobenzene, a...
Saved in:
Published in | The Journal of immunology (1950) Vol. 163; no. 7; pp. 3709 - 3717 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Am Assoc Immnol
01.10.1999
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we examined whether type 1 cytokine polarization by ribavirin in vivo could promote contact hypersensitivity (CHS) responses to dinitrofluorobenzene, a type 1 cytokine-mediated immune response. Unexpectedly, although type 1 cytokine responses were enhanced following ribavirin treatment in vitro and in vivo, the magnitude of CHS responses in BALB/c and C57BL/6 mice was influenced more by a second ribavirin-regulated pathway. The key regulatory molecule in this pathway was IL-10. Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. The effect of ribavirin on the expression of B7 molecules and on CHS responses was neutralized by IL-10 administration in BALB/c and by anti-IL-10 Ab in C57BL/6. Thus, ribavirin controlled CHS responses directly through the modulation of IL-10 expression, and in vivo outcome was dictated by the preferential expression of either B7-1, an inappropriate costimulatory molecule in CHS, or B7-2, the predominant costimulatory molecule in CHS. Replacing dinitrofluorobenzene priming with IFN-alpha stimulation, we showed that the ribavirin-regulated pathway could function independent of Ag priming. Altogether, these data showed that, although ribavirin treatment induced a type 1 cytokine bias in contact allergen-primed BALB/c and C57BL/6 mice, in vivo CHS responses were dependent on ribavirin-mediated regulation of both IL-10 and preferential costimulatory signaling. |
---|---|
AbstractList | We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we examined whether type 1 cytokine polarization by ribavirin in vivo could promote contact hypersensitivity (CHS) responses to dinitrofluorobenzene, a type 1 cytokine-mediated immune response. Unexpectedly, although type 1 cytokine responses were enhanced following ribavirin treatment in vitro and in vivo, the magnitude of CHS responses in BALB/c and C57BL/6 mice was influenced more by a second ribavirin-regulated pathway. The key regulatory molecule in this pathway was IL-10. Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. The effect of ribavirin on the expression of B7 molecules and on CHS responses was neutralized by IL-10 administration in BALB/c and by anti-IL-10 Ab in C57BL/6. Thus, ribavirin controlled CHS responses directly through the modulation of IL-10 expression, and in vivo outcome was dictated by the preferential expression of either B7-1, an inappropriate costimulatory molecule in CHS, or B7-2, the predominant costimulatory molecule in CHS. Replacing dinitrofluorobenzene priming with IFN- alpha stimulation, we showed that the ribavirin-regulated pathway could function independent of Ag priming. Altogether, these data showed that, although ribavirin treatment induced a type 1 cytokine bias in contact allergen-primed BALB/c and C57BL/6 mice, in vivo CHS responses were dependent on ribavirin-mediated regulation of both IL-10 and preferential costimulatory signaling. Abstract We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we examined whether type 1 cytokine polarization by ribavirin in vivo could promote contact hypersensitivity (CHS) responses to dinitrofluorobenzene, a type 1 cytokine-mediated immune response. Unexpectedly, although type 1 cytokine responses were enhanced following ribavirin treatment in vitro and in vivo, the magnitude of CHS responses in BALB/c and C57BL/6 mice was influenced more by a second ribavirin-regulated pathway. The key regulatory molecule in this pathway was IL-10. Ribavirin-mediated suppression of IL-10 in BALB/c mice was associated with increased B7-2 expression and enhanced CHS responses, whereas enhanced IL-10 levels, following ribavirin administration, led to increased B7-1 expression and impaired CHS responses in C57BL/6 mice. The effect of ribavirin on the expression of B7 molecules and on CHS responses was neutralized by IL-10 administration in BALB/c and by anti-IL-10 Ab in C57BL/6. Thus, ribavirin controlled CHS responses directly through the modulation of IL-10 expression, and in vivo outcome was dictated by the preferential expression of either B7-1, an inappropriate costimulatory molecule in CHS, or B7-2, the predominant costimulatory molecule in CHS. Replacing dinitrofluorobenzene priming with IFN-α stimulation, we showed that the ribavirin-regulated pathway could function independent of Ag priming. Altogether, these data showed that, although ribavirin treatment induced a type 1 cytokine bias in contact allergen-primed BALB/c and C57BL/6 mice, in vivo CHS responses were dependent on ribavirin-mediated regulation of both IL-10 and preferential costimulatory signaling. |
Author | Bard, Josie Pai, Bharati Lim, Charmaine Tam, Robert C |
Author_xml | – sequence: 1 fullname: Tam, Robert C – sequence: 2 fullname: Lim, Charmaine – sequence: 3 fullname: Bard, Josie – sequence: 4 fullname: Pai, Bharati |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10490966$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkdFu0zAUhi00xLrCEyAhX7EbUo7jxE4up2hjlSqBRuE2ctKTzsOxi-20hOfiAUnXIe2Om3OO5O__Zem7IGfWWSTkLYNFBln58UH3_WCdWTDBF3LBJZQvyIzlOSRCgDgjM4A0TZgU8pxchPAAAALS7BU5Z1MeSiFm5E_lbFRtpLfjDn1AG3TUex1Heodh52zAQG-cMe6g7Zbe6UbttdeWrj2q2KONdGnpd7139MrjdHdmQNvihjYjXU-VlNFqjO6Htki_OKO8_q2idvbD1L8dzONNXUeXq4QBvf618xjC47uyG1q5EHV_xJwf6Ve9tcpM_3hNXnbKBHzztOfk2831urpNVp8_LaurVdJmUMakgEKAzDkveZmpHBvZKQaqUVlayJZBITe8Qw4S0wbzVEIBwErWFI1Qm7RN-Zy8P_XuvPs5YIh1r0OLxiiLbgi1BOCiyLP_gkxyLvJpzgk_ga13IXjs6p3XvfJjzaA-Wq3_Wa0nq7Wsj1an1Lun-qHpcfMsc9I4AZcn4F5v7w_aYx16ZcyEs_pwODyr-gu5trI2 |
CitedBy_id | crossref_primary_10_1097_MCG_0b013e3182586f29 crossref_primary_10_1016_j_antiviral_2006_03_001 crossref_primary_10_1111_j_1365_2893_2005_00705_x crossref_primary_10_1111_j_1440_1746_2005_04024_x crossref_primary_10_1177_095632020301400101 crossref_primary_10_1002_jat_876 crossref_primary_10_1016_j_virusres_2004_11_007 crossref_primary_10_1016_S0731_7085_02_00323_0 crossref_primary_10_1016_S0168_8278_02_00353_7 crossref_primary_10_1128_AAC_47_4_1395_1398_2003 crossref_primary_10_1002_hep_21146 crossref_primary_10_1002_jhet_5570430212 crossref_primary_10_1016_j_vetimm_2015_01_001 crossref_primary_10_1021_cr1002563 crossref_primary_10_1016_S1413_8670_11_70208_2 crossref_primary_10_3390_genes13010046 crossref_primary_10_1016_j_antiviral_2004_09_002 crossref_primary_10_1128_AAC_44_5_1276_1283_2000 crossref_primary_10_1177_095632020101200501 crossref_primary_10_1016_j_fsi_2016_11_015 crossref_primary_10_1016_S1570_0232_02_00379_3 crossref_primary_10_4254_wjh_v7_i25_2590 |
Cites_doi | 10.4049/jimmunol.160.3.1320 10.1016/S0168-8278(96)80225-X 10.1093/infdis/174.6.1303 10.1016/S0168-8278(99)80093-2 10.1093/intimm/8.6.917 10.4049/jimmunol.153.9.4142 10.4049/jimmunol.126.3.861 10.1084/jem.185.9.1671 10.1056/NEJM198306163082403 10.1084/jem.182.1.99 10.1097/00007890-198902000-00038 10.1111/1523-1747.ep12413470 10.4049/jimmunol.161.4.2011 10.1007/BF00373351 10.1002/eji.1830260614 10.4049/jimmunol.154.6.2668 10.1002/eji.1830250940 10.1002/eji.1830250718 10.1084/jem.181.3.1145 10.1002/eji.1830260424 10.4049/jimmunol.157.2.522 10.1016/0167-5699(96)80606-2 10.1007/BF00189969 10.1016/S0952-7915(96)80122-1 10.1016/0092-8674(95)90349-6 10.1007/BF00171794 10.1128/iai.29.2.583-589.1980 10.1084/jem.166.5.1229 10.1128/AAC.22.1.108 10.1002/(SICI)1521-4141(199801)28:01<114::AID-IMMU114>3.0.CO;2-B 10.1172/JCI115300 10.1002/eji.1830251105 10.1097/00002371-199709000-00003 10.1111/1523-1747.ep12582809 10.1111/1523-1747.ep12393073 10.4049/jimmunol.136.7.2348 10.1084/jem.183.3.1001 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 7X8 |
DOI | 10.4049/jimmunol.163.7.3709 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1550-6606 |
EndPage | 3717 |
ExternalDocumentID | 10_4049_jimmunol_163_7_3709 10490966 www163_7_3709 |
Genre | Journal Article |
GroupedDBID | - 08R 2WC 34G 39C 3O- 53G 55 5GY 5RE 5VS 79B 85S 8RP AALRV AARDX ABEFU ABFLS ABOCM ABPPZ ABPTK ACGFS ACIWK ACNCT ACPRK ADACO ADBBV ADKFC AENEX AETEA AFFNX AFRAH AJYGW ALMA_UNASSIGNED_HOLDINGS BAWUL D0L DIK DU5 E3Z EBS EJD F5P FH7 FRP G8K GJ GX1 IH2 J5H K-O K78 KQ8 L7B MVM MYA NEJ O0- OK1 P0W P2P PQEST PQQKQ R.V RHF RHI RZQ SJN TWZ VH1 WH7 WOQ X X7M XFK XJT YCJ ZA5 ZE2 ZGI ZXP --- -~X .55 .GJ 18M ABCQX ABJNI ACGFO ADNWM AFHIN AFOSN AHWXS AI. AIZAD BTFSW CGR CUY CVF ECM EIF NPM TR2 W8F XSW XTH YHG AAYXX CITATION 7T5 H94 7X8 |
ID | FETCH-LOGICAL-c409t-8086075339394a5eb7fa10aba4287c1087d3fe307e2be5270800191b8b6ad2c23 |
ISSN | 0022-1767 |
IngestDate | Sat Aug 17 02:03:01 EDT 2024 Fri Aug 16 23:51:23 EDT 2024 Thu Sep 26 18:31:53 EDT 2024 Sat Sep 28 07:34:41 EDT 2024 Tue Nov 10 19:17:28 EST 2020 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c409t-8086075339394a5eb7fa10aba4287c1087d3fe307e2be5270800191b8b6ad2c23 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://journals.aai.org/jimmunol/article-pdf/163/7/3709/1109841/im199903709p.pdf |
PMID | 10490966 |
PQID | 17336517 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_70036854 proquest_miscellaneous_17336517 crossref_primary_10_4049_jimmunol_163_7_3709 pubmed_primary_10490966 highwire_smallpub1_www163_7_3709 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 1900 |
PublicationDate | 19991001 1999-Oct-01 1999-10-01 |
PublicationDateYYYYMMDD | 1999-10-01 |
PublicationDate_xml | – month: 10 year: 1999 text: 19991001 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of immunology (1950) |
PublicationTitleAlternate | J Immunol |
PublicationYear | 1999 |
Publisher | Am Assoc Immnol |
Publisher_xml | – name: Am Assoc Immnol |
References | 2023010209533517700_R29 2023010209533517700_R16 2023010209533517700_R38 2023010209533517700_R17 2023010209533517700_R39 2023010209533517700_R14 2023010209533517700_R36 2023010209533517700_R15 2023010209533517700_R37 2023010209533517700_R12 2023010209533517700_R34 2023010209533517700_R13 2023010209533517700_R35 2023010209533517700_R10 2023010209533517700_R32 2023010209533517700_R11 2023010209533517700_R33 2023010209533517700_R9 2023010209533517700_R30 2023010209533517700_R31 2023010209533517700_R1 2023010209533517700_R2 2023010209533517700_R3 2023010209533517700_R4 2023010209533517700_R5 2023010209533517700_R6 2023010209533517700_R7 2023010209533517700_R8 2023010209533517700_R18 2023010209533517700_R19 2023010209533517700_R27 2023010209533517700_R28 2023010209533517700_R25 2023010209533517700_R26 2023010209533517700_R23 2023010209533517700_R24 2023010209533517700_R21 2023010209533517700_R22 2023010209533517700_R41 2023010209533517700_R20 2023010209533517700_R40 |
References_xml | – ident: 2023010209533517700_R6 doi: 10.4049/jimmunol.160.3.1320 – ident: 2023010209533517700_R9 doi: 10.1016/S0168-8278(96)80225-X – ident: 2023010209533517700_R28 doi: 10.1093/infdis/174.6.1303 – ident: 2023010209533517700_R13 – ident: 2023010209533517700_R36 – ident: 2023010209533517700_R10 doi: 10.1016/S0168-8278(99)80093-2 – ident: 2023010209533517700_R32 doi: 10.1093/intimm/8.6.917 – ident: 2023010209533517700_R27 doi: 10.4049/jimmunol.153.9.4142 – ident: 2023010209533517700_R21 doi: 10.4049/jimmunol.126.3.861 – ident: 2023010209533517700_R29 doi: 10.1084/jem.185.9.1671 – ident: 2023010209533517700_R8 doi: 10.1056/NEJM198306163082403 – ident: 2023010209533517700_R22 – ident: 2023010209533517700_R14 doi: 10.1084/jem.182.1.99 – ident: 2023010209533517700_R41 doi: 10.1097/00007890-198902000-00038 – ident: 2023010209533517700_R23 doi: 10.1111/1523-1747.ep12413470 – ident: 2023010209533517700_R33 doi: 10.4049/jimmunol.161.4.2011 – ident: 2023010209533517700_R11 doi: 10.1007/BF00373351 – ident: 2023010209533517700_R15 doi: 10.1002/eji.1830260614 – ident: 2023010209533517700_R24 doi: 10.4049/jimmunol.154.6.2668 – ident: 2023010209533517700_R16 doi: 10.1002/eji.1830250940 – ident: 2023010209533517700_R17 doi: 10.1002/eji.1830250718 – ident: 2023010209533517700_R26 doi: 10.1084/jem.181.3.1145 – ident: 2023010209533517700_R31 doi: 10.1002/eji.1830260424 – ident: 2023010209533517700_R34 doi: 10.4049/jimmunol.157.2.522 – ident: 2023010209533517700_R4 doi: 10.1016/0167-5699(96)80606-2 – ident: 2023010209533517700_R39 doi: 10.1007/BF00189969 – ident: 2023010209533517700_R35 – ident: 2023010209533517700_R5 doi: 10.1016/S0952-7915(96)80122-1 – ident: 2023010209533517700_R25 doi: 10.1016/0092-8674(95)90349-6 – ident: 2023010209533517700_R37 doi: 10.1007/BF00171794 – ident: 2023010209533517700_R19 doi: 10.1128/iai.29.2.583-589.1980 – ident: 2023010209533517700_R2 doi: 10.1084/jem.166.5.1229 – ident: 2023010209533517700_R20 doi: 10.1128/AAC.22.1.108 – ident: 2023010209533517700_R30 doi: 10.1002/(SICI)1521-4141(199801)28:01<114::AID-IMMU114>3.0.CO;2-B – ident: 2023010209533517700_R3 doi: 10.1172/JCI115300 – ident: 2023010209533517700_R40 doi: 10.1002/eji.1830251105 – ident: 2023010209533517700_R7 doi: 10.1097/00002371-199709000-00003 – ident: 2023010209533517700_R38 doi: 10.1111/1523-1747.ep12582809 – ident: 2023010209533517700_R18 doi: 10.1111/1523-1747.ep12393073 – ident: 2023010209533517700_R1 doi: 10.4049/jimmunol.136.7.2348 – ident: 2023010209533517700_R12 doi: 10.1084/jem.183.3.1001 |
SSID | ssj0006024 |
Score | 1.8284909 |
Snippet | We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we examined... Abstract We previously described the promotion of type 1 cytokine responses by the nucleoside analogue, ribavirin, in human T cells in vitro. In this study, we... |
SourceID | proquest crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3709 |
SubjectTerms | Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Administration, Cutaneous AIDS/HIV Allergens - administration & dosage Allergens - immunology Animals Antigens, CD - biosynthesis B7-1 Antigen - biosynthesis B7-2 Antigen Cytokines - biosynthesis Cytokines - secretion Dermatitis, Contact - immunology Dermatitis, Contact - metabolism Dinitrofluorobenzene - administration & dosage Dinitrofluorobenzene - immunology Female Interferon-alpha - pharmacology Interleukin-10 - biosynthesis Lymph Nodes - cytology Lymph Nodes - immunology Lymph Nodes - secretion Membrane Glycoproteins - biosynthesis Mice Mice, Inbred BALB C Mice, Inbred C57BL Ribavirin - administration & dosage Ribavirin - pharmacology Signal Transduction - immunology Species Specificity Th1 Cells - drug effects Th1 Cells - metabolism Th1 Cells - secretion Th2 Cells - drug effects Th2 Cells - secretion |
Title | Contact Hypersensitivity Responses Following Ribavirin Treatment In Vivo Are Influenced by Type 1 Cytokine Polarization, Regulation of IL-10 Expression, and Costimulatory Signaling |
URI | http://www.jimmunol.org/cgi/content/abstract/163/7/3709 https://www.ncbi.nlm.nih.gov/pubmed/10490966 https://search.proquest.com/docview/17336517 https://search.proquest.com/docview/70036854 |
Volume | 163 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZbxMxELZCEYgXBOUKpx_gqdmwXu-u40cKrVoIBaFEyptl7yECabbaXAo_iF_AD2RmvVerVhwvq3jlvfR9sWfsb2YIeWkGYLLxMHZ4msaOH_LIMSJyncDVOvRdHfK4UFuchEdj__0kmHQ6P1uqpdXS9KMfl8aV_A-qcA5wxSjZf0C2vimcgN-ALxwBYTj-FcaYWgpjHL-CM5kvUIpe1oLIrfI1wWQLs1m2wfWAfGr0epqjrrEWl0NjPV1neyj_mlblSqxJikuzbC_aLrPvaIieoQtcxmwiLLmtYV-am8dDGGixWoBV1c4rTWiUwQhyih1xKx-1InpWzZXfGp62rOIpxqvYvFCvit03t7VWMbLs_dIs7Q5tMei6va-tVL9e_f5sy23vN6sbRUaESifXjjZgwpbsqEfscky01BSt8ZcLV7bmci5sYOjFecIHvwjnifKb-nDDvug3F7ezcp98Uofj4VCNDiaja-S6J2SATv674w_1jB-6nl9lpcd3tdmt8CGvL3nEeQuoykp9tYdTWDqjO-R2CQZ9Y_l2l3SS-S65YYuWbnfJzY-lHOMe-VUSkF4kIK0JSGsC0pqAtCYghQYSkAIBaUNAarYUCUgZrQhI2wTs0YZ-NEtpQT_a0K9HgXz0HPloTb77ZHx4MHp75JRlQJzId-USbKhBCIYt55JLXweJEalmrjYavf2IuQMR8zSBuSrxTBJ4An0gJpkZmFDHXuTxB2Rnns2TR4QG0hXGyMAIlvqaRzrSoWGRTFNPyyARXdKroFFnNtuLAi8ZkVQVkgqQVEIhkl1CK_jU4lTPZgAbU5vNpt3lRQWrgoEbd-P0PMlWC8UwEWnAxNU9BCaLGgR-lzy0fGi9ky9dGYaP_3jtE3Kr-Vs9JTvLfJU8AzN6aZ4XHP4N4CLRsw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Contact+hypersensitivity+responses+following+ribavirin+treatment+in+vivo+are+influenced+by+type+1+cytokine+polarization%2C+regulation+of+IL-10+expression%2C+and+costimulatory+signaling&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Tam%2C+R+C&rft.au=Lim%2C+C&rft.au=Bard%2C+J&rft.au=Pai%2C+B&rft.date=1999-10-01&rft.issn=0022-1767&rft.volume=163&rft.issue=7&rft.spage=3709&rft.epage=3717&rft_id=info:doi/10.4049%2Fjimmunol.163.7.3709&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon |